Principal investigator Dr Mikhail Kosiborod, of Saint Luke's Mid-America Heart Institute in Kansas City, said: "To our knowledge, this is the first trial of a pharmacologic agent to specifically target obesity as a treatment strategy for HFpEF, and the magnitude of the benefits we observed is the largest seen with any agent in HFpEF." He added: "This will likely have a significant impact on clinical practice, especially since there is a dearth of efficacious therapies in this vulnerable patient group." He also said that the findings should spark a change in the way obesity in people with heart failure is viewed, suggesting that, in HFpEF at least, "obesity is not simply a comorbidity in patients with HFpEF, but a root cause and a target for therapeutic intervention." The data provides another compelling endorsement for semaglutide, which is at the head of a series of new obesity therapies addressing GLP-1 and other targets, and keeps Novo Nordisk's drug ahead of challengers like Eli Lilly's combined GLP-1/GIP agonist Mounjaro (tirzepatide)
Molecular weight: ~4921.82 g/mol
We just end up talking about, you can take it in the short-term, but we dont know anything about whats going to happen if you take them in the short-term or the long-term, said Mehrotra
These supply the building blocks for glutathione production
However, synaptic plasticity and memory formation are impaired in GLP-1 receptor knockout mice (118)
For more context on fat loss peptide protocols , our comprehensive guides cover the full landscape of options
